William Mack & Associates’s Travere Therapeutics TVTX Stock Holding History

William Mack & Associates’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.01K	Buy	+119	New	+$7.27K	﹤0.01%	438

Other funds holding TVTX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

William Mack & Associates's TVTX Position: Q3 2026 in Review

William Mack & Associates opened a new position in Travere Therapeutics (TVTX) in Q3 2026: 119 shares worth $7.01K. The stake represents ﹤0.01% of the portfolio and ranks #438 among its holdings.

251 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

William Mack & Associates held 119 shares of Travere Therapeutics worth $7.01K as of Q3 2026.
Travere Therapeutics was a new William Mack & Associates position in Q3 2026.
Travere Therapeutics made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #438 holding.
251 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.